With the success of an AI-based early diagnosis solution for respiratory diseases in clinical trials, expectations are mounting that pneumonia can be diagnosed early via smartphone.

Nota (CEO Chae Myung-soo), a company specializing in AI lightweighting and optimization technology, has developed an AI solution for early pneumonia diagnosis using smartphones and completed clinical validation at Seongbuk Woori Children's Hospital, the largest specialized pediatric hospital in Korea.

This demonstration proved the effectiveness of the technology by recording an accuracy of over 86%.

Early response is crucial for respiratory diseases, including pneumonia, as they account for the leading cause of death among children and the elderly.

On the other hand, existing analog auscultation methods had limitations in diagnostic standardization due to the difficulty of data accumulation and objective analysis.

Nota is leading innovation in the medical field by developing breath sound analysis technology that applies AI algorithms to solve these problems.

Nota collaborated with Seongbuk Woori Children's Hospital to enhance its AI model based on respiratory sound data from children and adolescents.

In particular, while respiratory sound data for children under 10 years of age was previously very limited, this demonstration secured large-scale data and verified its potential for clinical use.

It was confirmed that accurate identification of abnormal breath sounds is possible by comparing and analyzing the collected breath sounds with hospital medical records.

The key to this technology is the stethoscope soundIt is a method of analyzing vibration sounds transmitted from the body.

This is a unique technology worldwide that overcomes the limitations of the existing medical environment and enables the early diagnosis of respiratory diseases.

Nota applies lightweighting and optimization technologies to AI models and provides them in the form of applications that can be run directly on smartphones.

This allows users to check their breathing status anytime and anywhere, and can be utilized in various medical environments such as telemedicine, home monitoring, and nursing hospitals.

Moving forward, Nota plans to expand the scope of its technology application to areas such as telemedicine, nursing facilities for the elderly, and chronic disease management by collaborating with specialized healthcare companies and medical institutions.

Furthermore, it can be rapidly introduced even in countries with insufficient medical infrastructure, laying the foundation for entry into the global market.

Chae Myeong-su, CEO of Nota, stated, “This pilot project is an important milestone demonstrating that Nota is evolving beyond a technology company into one that practically solves problems in the medical field,” adding, “We will continue to strengthen hospital partnerships and global cooperation to build a medical ecosystem centered on early diagnosis, remote monitoring, and prevention.”